Insider Purchases: Inside the Buy
Tag: CEOBuyIn
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
Insiders Are Buying Shares of Applied Optoelectronics. Should You?
Applied Optoelectronics (AAOI) insiders—including the CEO—are buying big while revenue growth accelerates and losses shrink. Institutions already own two-thirds of the stock. But with dilution risk, short sellers circling, and heavy competition, is AAOI a comeback kid—or just another speculative fiber bet?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
Arrow Electronics: A Straight Arrow, But the CEO Sees a Bullet
Arrow Electronics CEO Sean Kerins just bought nearly $1M of ARW stock. Is this undervalued tech distributor about to rebound, or just cruising under the radar? We take a shot at the bullseye—with puns and charts.
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
Does Align Technology’s Recovery Plan Have Teeth? The CEO Thinks So.
Align Technology insiders are smiling—because they’re buying. With a CEO purchase nearing $1M and Wall Street holding more shares than exist, ALGN may be regaining its shine. But should you sink your teeth into it now?
Viatris: The CEO Just Bought Shares… Should You Pop a Pill or Press "Buy"?
When a CEO personally buys over half a million dollars of stock, it’s time to pay attention. Viatris (VTRS) may be undervalued, with insider confidence, institutional backing, and a promising drug pipeline. But big losses and high debt mean it’s not risk-free. Is now the time to nibble?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?